Calcium channel blockers for primary Raynaud's phenomenon - Wikidata - awgldk - TriplyDB

Calcium channel blockers for primary Raynaud's phenomenon

Calcium channel blockers for primary Raynaud's phenomenon

http://www.wikidata.org/entity/Q24200938

about

Calcium channel blockers for primary Raynaud's phenomenon Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders Axillary Block-Induced Chemical Sympathectomy in the Setting of Digital Ischemia Nifedipine vs Placebo for Treatment of Chronic Chilblains: A Randomized Controlled Trial Botulinum toxin A in the treatment of Raynaud's phenomenon: a systematic review.Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.Behaviour change interventions for the management of Raynaud's phenomenon: a systematic review protocol.Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception.

P2860

Q24186106-CB63430D-F07D-48A1-9B4F-9556580C7444 Q27006921-FC7C7E55-1CDA-4C6D-B61A-21B64D8F118C Q28817319-5CB1E100-1FFA-42DE-8C45-12712E51297E Q33572167-33AE351D-0592-4A00-A8BB-27D2C9DF1346 Q36091433-C5E7A5F8-4777-4649-A6A9-977182471290 Q38538817-1A00D796-5ADD-4B89-A247-542838A81549 Q38638665-CD13547D-0178-4EFB-9680-1FE54886BD01 Q39031432-022B5265-F21B-475A-9102-570629B8C3F2

P2860

Calcium channel blockers for primary Raynaud's phenomenon

http://www.wikidata.org/entity/Q24200938

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Calcium channel blockers for primary Raynaud's phenomenon

@ast

Calcium channel blockers for primary Raynaud's phenomenon

@en

Calcium channel blockers for primary Raynaud's phenomenon

@en-gb

Calcium channel blockers for primary Raynaud's phenomenon

@nl

type

label

Calcium channel blockers for primary Raynaud's phenomenon

@ast

Calcium channel blockers for primary Raynaud's phenomenon

@en

Calcium channel blockers for primary Raynaud's phenomenon

@en-gb

Calcium channel blockers for primary Raynaud's phenomenon

@nl

prefLabel

Calcium channel blockers for primary Raynaud's phenomenon

@ast

Calcium channel blockers for primary Raynaud's phenomenon

@en

Calcium channel blockers for primary Raynaud's phenomenon

@en-gb

Calcium channel blockers for primary Raynaud's phenomenon

@nl

P1433

Q24200938-2E2BC92D-1BA5-424A-AF52-DF5C3A00F710

P1476

Q24200938-E0715957-2788-41CB-BB42-73EF2468A89A

P2093

Q24200938-7B97411A-4C64-4E78-8F1C-5D41493637B1

Q24200938-CE8B4FA9-6A48-46AF-9012-CDEA8EBC22A9

Q24200938-FFAA8264-EEF3-4FEE-8793-967F2A13B4C8

P2860

Q24200938-0ECD39B0-2F76-463C-96C1-6589E0202095

Q24200938-0FF3086F-32F0-4FA5-A86B-B349E93DFF0E

Q24200938-3FC2502B-2E3B-4278-ACEF-E70721945132

Q24200938-425D24E3-7F3F-4C7E-879D-5308EB060523

Q24200938-48BB002D-36D3-471F-9B75-0AA33223D77E

Q24200938-4CB2EA48-3476-4A34-B415-BBC7E880E434

Q24200938-54FA9CCF-EDC3-45E9-81EC-F07161269B9F

Q24200938-5A7867DA-BE80-4AA5-87AD-32543F497417

Q24200938-64738753-40DB-4BF5-A5B2-62F066C07460

Q24200938-6BE0C798-9883-4636-A2DD-DBFA3BA2D4A2

P304

Q24200938-F14952A3-0D11-451A-B1F6-68A034067096

P31

Q24200938-2462fb09-1399-4321-b5a3-7b44b15931cb

Q24200938-E95E2BAD-A789-4D00-9AE8-3EDB90494E02

P356

Q24200938-C357FE85-3CD4-4C86-BB51-B926F5C691FD

P433

Q24200938-11DB7673-F04B-4337-9080-4FC7EA898192

P50

Q24200938-95424377-AD68-4106-8F4D-F1FE43D58DED

P577

Q24200938-F7BCF7E7-0DF8-452E-9845-016D33276A8C

P698

Q24200938-54DB2CD2-EE69-4481-B090-E3FBF3A3C3BB

P356

14651858.CD002069.PUB4

P1433

Cochrane Database of Systematic Reviews

P1476

Calcium channel blockers for primary Raynaud's phenomenon

@en

P2093

Ariane L Herrick

http://www.w3.org/2001/XMLSchema#string

Jack Wilkinson

http://www.w3.org/2001/XMLSchema#string

Marina E Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Grading quality of evidence and strength of recommendations

What is "quality of evidence" and why is it important to clinicians?

Measuring inconsistency in meta-analyses

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Meta-analyses involving cross-over trials: methodological issues

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators.

A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon

Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud's phenomenon

The effect of metoprolol alone and combined metoprolol-felodipin on the digital microcirculation of patients with primary Raynaud's syndrome.

P304

CD002069

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/14651858.CD002069.PUB4

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24482037

http://www.w3.org/2001/XMLSchema#string